The very essence of translational medicine lies in integration of multi-layers of data and information from a wide array of disciplines. The transMed partners have been chosen to create a consortium with complementary and synergistic expertise, and where renowned experts from academia and several industry partners coordinately join forces. This, together with the sharp focus on a limited set of retinal diseases, shapes a first-rate platform for a multi-directional exchange of results, interpretations and knowledge, which would be unattainable at the level of individual projects.

Partners

1. Eberhard Karls Universität Tübingen
   (www.uni-tuebingen.de)
2. Università degli Studi di Modena e Reggio Emilia
   (www.unimore.it)
3. Lunds Universitet
   (www.lu.se)
4. Haskoli Islands
   (www.hi.is)
5. SP Process Development AB
   until 31.12.2017
6. InoCure
   (www.inocure.cz)
7. Oculis ehf. - terminated
8. PamGene International
   (www.pamgene.com)
9. RISE Research Institutes of Sweden
   from 01.01.2018
   (www.ri.se)

Partner Organisations

1. InnoSer BV
   (www.innoser.eu)
2. 2-BBB Medicines BV
   (www.2-bbb.com)
3. Biolog Life Science Institute
   (www.biolog.de)
4. Hannover Clinical Trial Center
   (www.clinical-trial-center.de)
5. NLO European Patent and Trade-mark Attorneys
   (www.nlo.eu)
6. European Vision Institute
   (www.europeanvisioninstitute.org)
7. Oculis ehf.
   (oculis.com)